Quarterly report [Sections 13 or 15(d)]

INTANGIBLE ASSETS (Details Narrative)

v3.26.3
INTANGIBLE ASSETS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 12, 2018
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Accumulated amortization   $ 53,055   $ 53,055   $ 36,440
Customer [Member]            
Amortization expense   8,474 $ 68,294 25,146 $ 156,631  
Intangible assets acquired fair value   336,200   336,200    
Accumulated amortization   53,055   $ 53,055    
Estimated useful lives       10 years    
Intellectual Property [Member]            
Amortization expense   0 295 $ 295 884  
Impairment   0   6,374    
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]            
Patent acquired purchase price $ 15,200          
Estimated useful lives 13 years          
Trademarks [Member]            
Intangible assets acquired fair value   249,500   249,500    
Impairment   $ 0 $ 0 $ 0 $ 0